Esters of (+)-alpha-(2,3-dimethoxyphenyl-[2-(4-flu rophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5HT2a receptor antagonist MDL 110,907

Details for Australian Patent Application No. 2004200993 (hide)

International Classifications

Event Publications

25 March 2004 Complete Application Filed

1 April 2004 Application Open to Public Inspection

Published as AU-A-2004200993

22 April 2004 Corrigenda

Complete Applications Filed - Name Index Under the name Aventis Pharmaceuticals Inc., Application No. 2004200993, under INID (54) correct the title to read Esters of (+)-alpha-(2,3-dimethoxyphenyl-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5HT2a receptor antagonist MDL 110,907.

17 April 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.